

BOSTON trial subgroup analysis¹

Impact of prior treatment with lenalidomide on SVd outcomes in relapsed/refractory multiple myeloma

Overall population

BOSTON study design²



BOSTON patients (N=402) were **randomized 1:1** to selinexor, bortezomib, and dexamethasone (SVd; n=195) OR bortezomib and dexamethasone (Vd; n=207) treatment (NCT03110562).*



Inclusion criteria: Patients ≥18 years with measurable myeloma (IMWG criteria); evidence of PD on/after previous treatment; 1–3 previous treatments for MM[†]

BOSTON study results²

BL characteristics:

- 2 groups were balanced
- Median age: **67 years** (IQR, 59–73)
- High-risk cytogenetic abnormalities: **192 (42%)**
- Median time since initial diagnosis: **3.7 years** (2.3–5.5)
- **19%** received 3 previous regimens

Follow-up duration:

SVd: **13.2 months**; Vd: **16.5 months**

Efficacy results


- **Primary endpoint – median PFS (95% CI):** SVd: **13.93 months (11.73–NE)**; Vd: **9.46 months (8.11–10.78)** (HR, 0.70 [95% CI, 0.53–0.93], **P=0.0075[‡]**)
- **Median OS:** Not reached in SVd; **25 months** in Vd; median follow-up, 17.3 and 17.5 months, respectively (HR, 0.84 [95% CI, 0.57–1.23], P=0.1852[‡])
- ORR (95% CI): SVd group (**76.4%** [69.8–82.2]) higher than Vd group (**62.3%** [55.3–68.9]); **P=0.0012[§]**

Safety results

- Most frequent grade 3–4 AEs with SVd: Thrombocytopenia (39%), anemia (16%), fatigue (13%), and pneumonia (12%)
- Peripheral neuropathy (≥grade 2) occurred less frequently with SVd versus Vd (21% vs 34%)
- Overall safety profile was manageable, with similar mortality rates with SVd versus Vd (24% vs 30%)

Post hoc analysis¹

Post hoc analysis of **PFS, OS, and safety** from the BOSTON trial (N=402)² for **lenalidomide-refractory[¶]** patient subgroup (n=106) (NCT03110562)[¶]




BL characteristics¹

106 lenalidomide-refractory patients: SVd (n=53) and Vd (n=53)

Follow-up duration: SVd: **28.2 months**; Vd: **27.1 months**

Consistent with overall study population



Results¹

Efficacy: PFS¹

In the lenalidomide-refractory subgroup, clinically meaningful improvements in PFS were observed with SVd versus Vd

Lenalidomide-refractory PFS (months)[‡]

P=0.006

SVd **10.2** months
Vd **7.1** months

HR (95% CI), 0.52 (0.31–0.99)

Supports another treatment option for RRMM populations with lenalidomide-refractory disease¹

Lenalidomide-refractory OS (months)[‡]

P=0.015

SVd **26.7** months
Vd **18.6** months

HR (95% CI), 0.53 (0.30–0.95)

Efficacy: OS¹

The median OS in the lenalidomide-refractory subgroup was **8 months** longer with SVd versus Vd

Safety¹

- Lenalidomide-refractory group median time to discontinuation: 6.1 months for SVd; 4.7 months for Vd
- Consistent with BOSTON primary analysis

TRAE, n (%)	Lenalidomide-refractory	
	SVd (n=53)	Vd (n=52)
Hematologic		
Thrombocytopenia	24 (45)	16 (31)
Anemia	4 (8)	2 (4)
Neutropenia	2 (4)	1 (2)
Non-hematologic		
Fatigue	5 (9)	0
Nausea	5 (9)	0
Diarrhea	6 (11)	0
Neuropathy peripheral	2 (4)	4 (8)
Asthenia	1 (2)	1 (2)
Cataract	7 (13)	1 (2)
Vomiting	4 (8)	0

Table 1. Grade 3–4 TRAEs occurring in >5% of patients in the lenalidomide-refractory subgroup

Secondary endpoints in the lenalidomide-refractory subgroup¹

In the SVd group versus Vd group:

ORR was **higher** (P=0.009) (**67.9%** versus **47.2%**; OR, 2.59 [95% CI, 1.17–5.77])[§]

VGPR was **higher** (P=0.109) (**35.8%** versus **24.5%**; OR, 1.74 [95% CI, 0.72–4.21])

Median TTNT was **longer** (P=0.006): **13.0 months** versus **7.6 months**



Conclusion¹

BOSTON post hoc analysis shows **clinically meaningful outcomes and a manageable safety profile** in the SVd treatment arm over Vd arm for RRMM patients with lenalidomide-refractory disease, supporting an additional viable treatment option.



*SVd arm: 5-week cycles including oral selinexor 100 mg (days 1, 8, 15, 22, 29), bortezomib 1.3 mg/m² SC once per week (days 1, 8, 15, 22), oral dexamethasone 20 mg (days 1, 2, 8, 9, 15, 16, 22, 23, 29, 30). Vd arm: bortezomib 1.3 mg/m² SC (days 1, 4, 8, 11) and oral dexamethasone 20 mg (days 1, 2, 4, 5, 8, 9, 11, 12) during eight 3-week cycles; starting at cycle 9, each cycle 5 weeks with bortezomib given on days 1, 8, 15, and 22 and dexamethasone on days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30. Dose modifications were allowed to help manage tolerability. [†]Patients with systemic light-chain amyloidosis, central nervous system involvement, or grade 2 painful or grade ≥2 peripheral neuropathy were excluded from the study. [‡]Compared using stratified log-rank test. HRs and CIs estimated with a stratified Cox proportional-hazards model with treatment as the single variate. [§]OR for ORR calculated with Cochran–Mantel–Haenszel χ^2 test. [¶]Lenalidomide-refractory status was defined as PD within 60 days of lenalidomide treatment or best response of stable disease or PD. [¶]Post hoc analysis also included PI-naïve (n=95), bortezomib-naïve (n=123), and 1LOT (n=198) subgroups. 1LOT, one prior line of therapy; AE, adverse event; BL, baseline; CI, confidence interval; HR, hazard ratio; IMWG, International Myeloma Working Group; IQR, interquartile range; MM, multiple myeloma; NE, not evaluable; OR, odds ratio; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PI, proteasome inhibitor; RRMM, relapsed/refractory MM; SC, subcutaneously; SVd, selinexor + bortezomib + dexamethasone; TRAE, treatment-related adverse event; TTNT, time to next treatment; Vd, bortezomib + dexamethasone; VGPR, very good partial response.

1. Mateos M, et al. *Eur J Haematol.* 2024;113(2):242–252. 2. Grosicki S, et al. *Lancet.* 2020;396(10262):1563–1573.

This content has been developed in partnership with Menarini Stemline. This content has been sponsored by Menarini Stemline. The content hosted on this platform is intended for educational purposes. Any data about non-Menarini Stemline products are based on publicly available information. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This educational activity is intended for healthcare professionals only.

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit–risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to Menarini Stemline. Please refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country for further information. MED-GL-2600013, March 2026.